Dr Reddy’s Laboratories’ net profit fell 36% to ₹925 crore for July to September. Revenue slipped 1.5% to ₹8,671 crore.
North America sales fell 23% to ₹2,490 crore, against a high base last year when generic Revlimid sales were strong. India sales rose 17% and emerging markets 24%. The EBITDA margin recovered to 20.6% from 16.3% in the June quarter.
